98%
921
2 minutes
20
Introduction: Platinum-based drugs, the most widely used chemotherapeutic drugs in clinical oncology, have long faced the problem of drug resistance, which is urgently in need of resolution. Identifying biomarkers of drug resistance may help reduce platinum resistance and improve therapeutic efficacy.
Objectives: This study aims to identify potential biomarkers associated with the development of cisplatin resistance in non-small cell lung cancer (NSCLC) and explore mechanisms to overcome chemoresistance.
Methods: NSCLC cisplatin resistance cell lines were constructed, and transcriptome sequencing was performed. Results were validated using Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Molecular docking, proteomics sequencing, and in vitro and in vivo experiments were conducted to evaluate the role of Heme Oxygenase 1 (HO-1) in cisplatin resistance.
Results: NSCLC cisplatin resistance cell lines, GEO and TCGA data identified HMOX1, downstream of Nrf2, as a key drug resistance gene induced by cisplatin. Activation of the Nrf2/HO-1 pathway was found to induce ferroptosis resistance, a critical mechanism of cisplatin resistance. Candidate compounds SB 202190 and Nordihydroguaiaretic acid (NDGA) effectively reactivated ferroptosis by inhibiting HO-1, thereby increasing cisplatin sensitivity.
Conclusion: The Nrf2/HO-1 pathway is a significant contributor to cisplatin resistance in NSCLC. Targeting HO-1 with SB 202190 and NDGA presents a promising strategy to overcome resistance and improve chemotherapy outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jare.2025.05.033 | DOI Listing |
Eur J Pharm Sci
September 2025
Department of Organic Chemistry, University of Debrecen, P.O. Box 400, H-4002 Debrecen, Hungary. Electronic address:
Platinum-group metal half-sandwich complexes are considered to be potential replacements of the clinically widely used platins which have several side effects and tend to cause resistance to develop. In our previous works, we used a range of 2-pyridyl-substituted N- and C-glycosyl heterocycles as N,N-chelating ligands to prepare ruthenium(II), osmium(II), iridium(III) and rhodium(III) polyhapto arene/arenyl half-sandwich complexes. Some of these complexes, particularly with the C-glucopyranosyl isoxazole derived ligand in its O-perbenzoylated form, exhibited greater anticancer efficiency than cisplatin and had minimal or negligible effects on non-transformed fibroblasts.
View Article and Find Full Text PDFBiochim Biophys Acta Mol Cell Res
September 2025
Department of Clinical Laboratory, North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Care Hospital-Tangshan, China; Key Laboratory of Molecular Medicine for Abnormal Development and Related Diseases in Tangshan City-Tangshan, China. Electronic address: wu
Cisplatin resistance continues to be a major obstacle in the treatment of ovarian cancer (OC). Gap junction protein β-2 (GJB2), a key member of the connexin family, is well-known for its association with hereditary deafness. However, its role in ovarian cancer chemotherapy resistance remains unexplored.
View Article and Find Full Text PDFJ Inorg Biochem
September 2025
State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Road, Guilin 541004, PR China. Electronic address:
This study reports the synthesis and antitumor evaluation of six novel dinuclear calcium(II) complexes with the general formula [Ca(μ-O)(QM)(QH)], designated as CaQ1 through CaQ6. These complexes incorporate various deprotonated 8-hydroxyquinoline ligands (H-QM-H-QM) and 1,10-phenanthroline derivatives (QH), synthesized using Ca(NO)·4HO. The specific compositions are as follows: CaQ1: H-QM = 5,7-dibromo-8-hydroxyquinoline (x = 1), QH = bathophenanthroline; CaQ2: H-QM = 5,7-dichloro-8-quinolinol (x = 2), QH = bathophenanthroline; CaQ3: H-QM = 5,7-diiodo-8-hydroxyquinoline (x = 3), QH = 1,10-phenanthroline; CaQ4: H-QM = 5,7-dichloro-8-quinolinol (x = 2), QH = 1,10-phenanthroline; CaQ5: H-QM = clioquinol (x = 4), QH = 1,10-phenanthroline; CaQ6: H-QM = 5,7-dibromo-8-hydroxyquinoline (x = 1), QH = 1,10-phenanthroline.
View Article and Find Full Text PDFDNA Repair (Amst)
August 2025
Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Erasmus University Med
DNA crosslink-inducing drugs are widely used in clinical settings for treatment of solid tumors. Double strand breaks (DSBs) that arise during interstrand crosslink (ICL) repair are crucial determinants of the therapeutic response, as they lead to cell death if not repaired. DSBs can be repaired through non-homologous end joining (NHEJ), theta-mediated end joining (TMEJ), and homologous recombination (HR).
View Article and Find Full Text PDFChem Biol Interact
September 2025
Department of Human Development and Family Studies, National Taiwan Normal University, Taipei 10610, Taiwan; Nutrition Science, School of Life Science, National Taiwan Normal University, Taipei 11677, Taiwan. Electronic address:
Accumulated dysfunctional mitochondria are involved in tumorigenesis, and it is conceivable that mitophagy, a selective form of autophagic degradation of mitochondria, plays a tumor-suppressive role. Our bioinformatics analysis identified lignan justicidin A (JA) as a potential mitophagy inducer. In HRAS-mutant human bladder cancer T24 cells, JA reduced population cell growth, changed mitochondrial membrane potential, and induced autophagy.
View Article and Find Full Text PDF